Salvage Therapy for Relapsed/Refractory Testicular Germ Cell Tumors: King Faisal Hospital and Research Center, Riyadh Experience

Read full text
Authors: Muhammad Shahzad Rauf, Hazzaa Abdulla Alzahrani, Ali M. Alhanash, Fahad A. Almugbel, Ali AlQahtani, Ahmed Alzahrani, Tusneem Ahmed M. Elhassan, Huda Syed, Mohammed Ghannam Thallab Alharbi, Ali H. Aljubran, Shouki N. Bazarbashi
Cited by: 0
References: 13

Abstract

Purpose: Optimal salvage treatment for relapsed/refractory germ cell tumors in men remains controversial. The options include conventional-dose chemotherapy (CDCT) and high-dose chemotherapy with autologous stem cell transplantation (HDCT-ASCT). There is currently a lack of data from the Middle East on this topic. This study presents the largest single-institution experience in the region. Methods: We retrospectively examined patients aged 14 years or older, treated at King Faisal Hospital and Research Center, Riyadh, between 2010 and 2022. Patients previously received first-line, cisplatin-based chemotherapy. The treatment consisted of either CDCT or HDCT-ASCT. The primary endpoints were event-free survival (EFS) and overall survival (OS). Results: Study included 46 patients, of whom 24 and 22 received CDCT and HDCT-ASCT, respectively. Using the IPFSG prognostic model as per local institutional practice, patients in the very low, low, and intermediate risk groups received CDCT. In the 24-patient CDCT group, 16 (66%) were high/very high risk, and only 2 (8%) demonstrated primary refractoriness. Contrarily, of the 22 patients who received HDCT-ASCT, 20 (91%) were classified as high/very high risk, and 17 (77%) were primary refractory to first-line treatment. The HDCT-ASCT cohort was heavily weighted toward high/very high risk. HDCT-ASCT group (59%) had a higher complete remission rate than the CDCT group (59% vs 41%). With a median follow-up of 35 months, the 3-year OS was 60% in the CDCT group and 53% in the HDCT-ASCT group, whereas the 3-year EFS rates were 54% and 43%, respectively. Discussion: Results indicated that HDCT-ASCT achieved a superior response rate compared with CDCT, despite an adverse prognostic profile and numerically comparable survival outcomes with the lower-risk cohort treated with CDCT. These findings suggest that the selection of higher-risk patients for a more intensive therapy is an effective strategy. However, direct comparison is limited by the retrospective nature.

Fields of Study & Subjects

Testicular diseases and treatments Childhood Cancer Survivors' Quality of Life Sarcoma Diagnosis and Treatment

Publication details

Journal / source
Research and Reports in Urology
Volume
Volume 18
Pages
1–10
Publication date
1 March 2026
Language
EN